home / stock / embi / embi quote
Last: | $0.09 |
---|---|
Change Percent: | 0.0% |
Open: | $0.0925 |
Close: | $0.09 |
High: | $0.1 |
Low: | $0.088 |
Volume: | 6,962,748 |
Last Trade Date Time: | 01/18/2021 04:54:29 pm |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$0.09 | $0.0925 | $0.09 | $0.1 | $0.088 | 6,962,748 | 01-18-2021 |
$0.09 | $0.0925 | $0.09 | $0.1 | $0.088 | 6,962,748 | 01-15-2021 |
$0.0885 | $0.102 | $0.0885 | $0.1099 | $0.0725 | 12,606,007 | 01-14-2021 |
$0.096 | $0.0689 | $0.096 | $0.1195 | $0.059 | 47,891,391 | 01-13-2021 |
$0.063 | $0.046 | $0.063 | $0.064 | $0.046 | 32,020,472 | 01-12-2021 |
$0.046 | $0.0425 | $0.046 | $0.0475 | $0.04 | 9,340,068 | 01-11-2021 |
$0.041 | $0.0465 | $0.041 | $0.0465 | $0.0395 | 5,044,252 | 01-08-2021 |
$0.0395 | $0.041 | $0.0395 | $0.05 | $0.0395 | 7,853,086 | 01-07-2021 |
$0.04 | $0.0436 | $0.04 | $0.047 | $0.0395 | 9,139,227 | 01-06-2021 |
$0.042 | $0.044 | $0.042 | $0.05 | $0.0385 | 7,173,037 | 01-05-2021 |
$0.0401 | $0.04 | $0.0401 | $0.0456 | $0.0393 | 3,117,780 | 01-04-2021 |
$0.04 | $0.0405 | $0.04 | $0.042 | $0.0355 | 1,648,924 | 01-01-2021 |
$0.04 | $0.0405 | $0.04 | $0.042 | $0.0355 | 1,648,924 | 12-31-2020 |
$0.04 | $0.037485 | $0.04 | $0.0422 | $0.036 | 2,669,328 | 12-30-2020 |
$0.04 | $0.041 | $0.04 | $0.0434 | $0.035 | 2,493,394 | 12-29-2020 |
$0.041 | $0.05 | $0.041 | $0.055 | $0.0351 | 3,881,397 | 12-28-2020 |
$0.0465 | $0.046 | $0.0465 | $0.052 | $0.043 | 2,520,775 | 12-25-2020 |
$0.0465 | $0.046 | $0.0465 | $0.052 | $0.043 | 2,520,775 | 12-24-2020 |
$0.045 | $0.04 | $0.045 | $0.046 | $0.039 | 2,883,868 | 12-23-2020 |
$0.0423 | $0.05885 | $0.0423 | $0.0589 | $0.04 | 3,867,892 | 12-22-2020 |
News, Short Squeeze, Breakout and More Instantly...
Emerald Bioscience Inc Company Name:
EMBI Stock Symbol:
OTCMKTS Market:
San Diego, Calif., March 08, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with s...
San Diego, Calif., March 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with s...
San Diego, Calif., Feb. 03, 2021 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (OTCQB: SKYE) (“SKYE” or the “Company”), a biopharmaceutical company focused on developing proprietary, synthetic cannabinoid-derived molecules to treat glaucoma and other diseases with si...